---
title: UK pharma media reputation tracker – 2026 year to date
canonical_url: https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd
type: dataset
publisher: Omniscan
sector: Pharma in the UK
period: 2026 year to date
coverage_start: '2026-01-01'
coverage_end: '2026-10-31'
date_published: '2026-11-03'
last_updated: '2026-11-03'
organisations: 10
articles_analysed: 8279
mentions: 6999
data_download: https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd/data.json
summary: AstraZeneca had the highest average monthly share of coverage (23.5%) among
  10 companies in UK earned media from 1 January 2026 to 31 October 2026, ahead of
  Eli Lilly (20.7%) and Novo Nordisk (18.9%).
---

# UK pharma media reputation tracker: 2026 year to date (1 January 2026–31 October 2026)

> AstraZeneca had the highest average monthly share of coverage (23.5%) among 10 companies in UK earned media from 1 January 2026 to 31 October 2026, ahead of Eli Lilly (20.7%) and Novo Nordisk (18.9%). Moderna had the most favourable net tone (+59). Omniscan analysed 8,279 articles containing 6,999 mentions of the companies tracked.

Interactive version: https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd

## Pharma in the UK ranking by share of coverage, 2026 year to date

| Rank | Organisation | Average monthly share of coverage | Mentions | Positive | Neutral | Negative | Net tone |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | AstraZeneca | 23.5% | 1,734 | 54% | 35% | 11% | +43 |
| 2 | Eli Lilly | 20.7% | 1,398 | 33% | 53% | 14% | +19 |
| 3 | Novo Nordisk | 18.9% | 1,298 | 26% | 59% | 15% | +12 |
| 4 | GSK | 18.8% | 1,319 | 56% | 37% | 7% | +49 |
| 5 | Pfizer | 4.1% | 282 | 25% | 51% | 24% | 0 |
| 6 | MSD | 3.3% | 218 | 41% | 39% | 20% | +21 |
| 7 | Novartis | 2.9% | 206 | 42% | 48% | 10% | +32 |
| 7 | Roche | 2.9% | 200 | 42% | 43% | 15% | +27 |
| 9 | Sanofi | 2.5% | 174 | 30% | 41% | 29% | +1 |
| 10 | Moderna | 2.4% | 170 | 63% | 33% | 4% | +59 |

## Monthly share of coverage, Pharma in the UK

| Organisation | January 2026 | February 2026 | March 2026 | April 2026 | May 2026 | June 2026 | July 2026 | August 2026 | September 2026 | October 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| AstraZeneca | 18.4% | 20.2% | 13.9% | 24.1% | 20.1% | 13.5% | 29.2% | 34.3% | 30.3% | 31.2% |
| Eli Lilly | 26.2% | 27.5% | 29.3% | 18.7% | 22.6% | 17.1% | 11.9% | 25.0% | 14.6% | 13.7% |
| Novo Nordisk | 22.4% | 20.0% | 19.7% | 19.6% | 18.5% | 23.5% | 16.9% | 19.7% | 15.8% | 12.7% |
| GSK | 13.5% | 20.5% | 17.7% | 15.3% | 17.6% | 27.1% | 23.9% | 8.8% | 20.6% | 23.3% |
| Pfizer | 6.1% | 3.4% | 4.6% | 5.3% | 3.1% | 5.3% | 4.2% | 1.6% | 3.0% | 4.0% |
| MSD | 2.7% | 2.5% | 2.3% | 3.5% | 7.2% | 2.8% | 2.6% | 3.3% | 2.8% | 3.4% |
| Novartis | 3.3% | 1.3% | 2.9% | 2.6% | 3.1% | 2.2% | 5.2% | 1.4% | 3.7% | 3.2% |
| Roche | 2.9% | 0.3% | 5.2% | 3.4% | 3.1% | 2.3% | 2.8% | 1.2% | 4.2% | 3.3% |
| Sanofi | 3.2% | 2.3% | 4.0% | 3.2% | 1.6% | 3.3% | 1.4% | 1.4% | 2.5% | 2.4% |
| Moderna | 1.2% | 2.0% | 0.4% | 4.3% | 3.1% | 2.8% | 2.0% | 3.2% | 2.5% | 2.8% |

## Companies in detail

### AstraZeneca

**Oncology, dealmaking and investment define AstraZeneca’s year-to-date coverage**

AstraZeneca ranked 1st of 10 by average monthly share of coverage (23.5%) in the Pharma in the UK benchmark for 2026 year to date, with 1,734 mentions and a net tone of +43.

AstraZeneca led the benchmark from January to October with 1,734 measured mentions, a 24.8% pooled share of tracked-company mentions and first place on both pooled and average monthly share. Its 23.5% average monthly share was below its pooled share because the latter gave greater weight to the higher-volume months later in the window. Its monthly rank ranged from first to fourth during the first half, including first place in April, before it ranked first continuously from July through October. Early coverage combined the CSPC obesity collaboration, a $15bn China investment programme and the agreement to acquire Modella AI. Results reporting then emphasised cancer-drug demand and pipeline growth, while March brought positive tozorakimab data alongside mixed results for efzimfotase alfa. The £300m commitment to Cambridge and Macclesfield gave April and May a substantial UK investment strand after earlier reporting on paused projects. Coverage in June broadened around elecoglipron’s phase-two results, NHS discussions over Enhertu and the company’s use of AI in drug development. July paired strong oncology-led financial results and the Dizal lung-cancer licensing agreement with the failed Wainua trial. August’s reported Bristol Myers Squibb merger discussions, their subsequent denial and the halted volrustomig study produced a markedly different agenda. The closing months combined the $2bn Summit Therapeutics investment, NHS approval for Enhertu and third-quarter results with a restructuring programme intended to redirect savings into the pipeline.

Key messages:

- AstraZeneca accounted for 24.8% of tracked-company mentions; its monthly rank ranged from first to fourth among ten companies.
- Coverage concentrated on Financial Results & Pipeline and M&A & Licensing.
- Visibility peaked in August 2026 at 34.3%, compared with 13.5% in June 2026.
- January 2026: AstraZeneca agreed an $18.5bn collaboration with CSPC covering weight-management and diabetes programmes, reported by The Independent.

Leading themes:

- Financial Results & Pipeline: 27.7% of AstraZeneca's coverage (theme index 2.38, net tone +44)
- M&A & Licensing: 23.5% of AstraZeneca's coverage (theme index 1.78, net tone +43)
- Clinical Trials & Research: 17.3% of AstraZeneca's coverage (theme index 1.53, net tone +40)

Notable positive coverage:

- 30 October 2026, france24.com: [Drugs giant AstraZeneca reveals higher profits, savings plan](https://www.france24.com/en/live-news/20261030-drugs-giant-astrazeneca-reveals-higher-profits-savings-plan-1). AstraZeneca reported a 23% rise in third-quarter net profit to $3.12 billion and record quarterly revenue of $16.2 billion, supported by cancer medicines. It also announced a restructuring programme targeting $1.5 billion in annual savings for reinvestment in its pipeline, while saying there would be job losses but no net reduction in employment.
- 27 July 2026, euronews.com: [AstraZeneca quarterly net profit rises 2% on strong cancer drug sales](https://www.euronews.com/business/2026/07/27/astrazeneca-quarterly-net-profit-rises-2-on-strong-cancer-drug-sales). AstraZeneca reported higher second-quarter profit and revenue, driven by cancer and rare-disease medicine sales, and maintained its 2026 outlook. The company is also advancing an experimental obesity pill following a setback for Wainua.
- 10 February 2026, independent.co.uk: [AstraZeneca profits jump by 40% amid strong demand for cancer drugs](https://www.independent.co.uk/news/business/astrazeneca-shares-china-swedish-b2917290.html). AstraZeneca reported a 40% increase in annual pre-tax profit and forecast further earnings growth in 2026. It cited cancer-drug demand, clinical development and weight-loss medicine investment as drivers of its strategy.

Notable negative coverage:

- 8 September 2026, cnbc.com: [Cramer's lightning round: 'I am not going to put my money on AstraZeneca'](https://www.cnbc.com/2026/09/08/cramers-lightning-round-i-am-not-going-to-put-my-money-on-astrazeneca.html). Jim Cramer says he would not invest in AstraZeneca, citing concern that the company has missed clinical trials. The comments appear in a rapid-fire stock-picking segment.
- 19 July 2026, thetimes.com: [AstraZeneca needs a shot in the arm to hit $80bn revenue target](https://www.thetimes.com/business/companies-markets/article/astrazeneca-under-pressure-meet-80bn-revenue-target-results-nyse-z57bsv3bn). AstraZeneca faces investor pressure after its Wainua phase III trial failure, which cut its market value and raised doubts about its $80bn 2030 sales target. The article assesses pipeline readouts, patent-expiry risks and the company's strategy under Pascal Soriot.
- 14 July 2026, cnbc.com: [HSBC loses conviction in leading drugmaker, forecasts 'tough path' ahead](https://www.cnbc.com/2026/07/14/hsbc-astrazeneca-forecasts-tough-path-ahead.html). HSBC downgraded AstraZeneca after a late-stage heart-disease trial failed and cut its target price. The report says further trial setbacks could weaken investor confidence in the company's R&D engine.

- [AstraZeneca deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd?entity=astrazeneca&view=deep-dive)
- [AstraZeneca PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd/reports/astrazeneca.pdf)

### Eli Lilly

**Foundayo launch broadened Lilly’s agenda beyond Mounjaro**

Eli Lilly ranked 2nd of 10 by average monthly share of coverage (20.7%) in the Pharma in the UK benchmark for 2026 year to date, with 1,398 mentions and a net tone of +19.

Eli Lilly recorded 1,398 mentions, representing 20% of tracked-company mentions across January to October, and ranked second on both pooled and average monthly share. It led the cohort from January to March, as its share rose from 26.2% to 29.3%. Early coverage centred on Mounjaro use, safety, supply and unequal NHS access, alongside February trial results comparing orforglipron with oral semaglutide. March added Lilly’s agreement to acquire Centessa for up to $7.8bn and its call for NHS pricing reform before resuming paused UK investment. Share fell to 18.7% and third place in April, before returning to first at 22.6% in May; stories during this period included the UK paediatric approval of Mounjaro and research on maintaining weight loss with orforglipron. June and July brought successive declines to 17.1% and 11.9%, moving Lilly from third to fourth place. Stories included the UK launch of LillyDirect, government-backed obesity-care pilots and the proposed acquisition of AtaiBeckley for up to $3.8bn. August marked the strongest recovery, with share rising 13.1 percentage points to 25% and second place as Foundayo received UK authorisation and launched privately. Share subsequently fell to 14.6% in September and 13.7% in October, while coverage included retatrutide trial results, European regulatory backing for Foundayo and stronger third-quarter sales of Mounjaro and Zepbound. Overall, the period moved from a predominantly Mounjaro-led profile towards a broader account encompassing oral obesity treatment, neuroscience acquisitions, direct distribution, access policy and pipeline performance.

Key messages:

- Eli Lilly accounted for 20% of tracked-company mentions, with its monthly rank ranging from first to fourth among ten companies.
- Coverage concentrated on Medicines Safety, Supply & Patient Use and NHS Access & Pricing.
- Visibility peaked in March 2026 at 29.3%, compared with 11.9% in July 2026.
- January 2026: The BMJ reported that one fifth of local areas in England still lacked NHS access to Mounjaro.

Leading themes:

- Medicines Safety, Supply & Patient Use: 53.5% of Eli Lilly's coverage (theme index 4.23, net tone +1)
- NHS Access & Pricing: 14.4% of Eli Lilly's coverage (theme index 1.71, net tone +9)
- Drug Approvals & Launches: 12.1% of Eli Lilly's coverage (theme index 1.92, net tone +79)

Notable positive coverage:

- 9 February 2026, bbc.com: [Weight-loss jab Mounjaro helped Nottinghamshire woman find cancer](https://www.bbc.com/news/articles/cn0yl9v0x4go). A Nottinghamshire woman says weight loss while taking Mounjaro helped her discover a breast lump and receive a cancer diagnosis. The article also notes common and rare reported side effects of the medicine.
- 14 July 2026, walesonline.co.uk: [Woman overcame phobia and judgment to lose 100lbs in a year](https://www.walesonline.co.uk/news/health/woman-overcame-phobia-judgment-lose-34289104). A Newcastle woman described losing more than 100lb after using Eli Lilly's Mounjaro through a digital pharmacy. The article also discusses stigma around weight-loss injections and common gastrointestinal side effects.
- 27 October 2026, mirror.co.uk: [NHS GP gives Mounjaro Wegovy Saxenda 'cheating' rant over results](https://www.mirror.co.uk/news/health/nhs-gp-gives-mounjaro-wegovy-37811873). An NHS GP argues that GLP-1 weight-loss medicines are evidence-based treatments rather than "cheating", citing their role in managing appetite and obesity. Patient comments describe substantial weight loss and health improvements with Mounjaro, while one highlights the high private cost of treatment.

Notable negative coverage:

- 28 September 2026, theguardian.com: [‘It’s problematic’: concern as weight-loss jab maker sponsors Vogue World event](https://www.theguardian.com/fashion/2026/sep/27/weight-loss-pill-company-eli-lilly-vogue-world-ties-concerns-health-campaigners). Critics, including eating-disorder advocates and academics, criticised Eli Lilly's sponsorship of Vogue World in Milan, arguing it may reinforce thinness ideals and normalise medical weight loss as a lifestyle choice. Lilly said the partnership was intended to shift discussion of weight from aesthetics towards health; the article notes the UK approval of its weight-loss pill.
- 30 October 2026, thesun.co.uk: [I lied to get weight loss jabs... I was so ill I thought I'd die](https://www.thesun.co.uk/fabulous/32782501/lied-ozempic-weight-loss-jabs-side-effects/). Danielle Mason describes obtaining Eli Lilly’s Mounjaro privately by misrepresenting her weight and experiencing severe gastrointestinal symptoms, anxiety and panic attacks after increasing her dose. An NHS GP warns that use outside licensed eligibility criteria, incomplete medical disclosures and potential drug interactions can be dangerous.
- 30 October 2026, theguardian.com: [Everyone is thin and we're not allowed to say so: the toxic legacy of body positivity](https://www.theguardian.com/lifeandstyle/2026/oct/30/body-positivity-ozempic-thinness). The article examines the cultural backlash against renewed thinness ideals in the GLP-1 era, citing Eli Lilly’s sponsorship of Vogue World Milano. Eating-disorder advocates criticise the association of the fashion event with Lilly, manufacturer of Mounjaro and Zepbound, while the company says it aims to shift discussion of weight from aesthetics to health.

- [Eli Lilly deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd?entity=elililly&view=deep-dive)
- [Eli Lilly PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd/reports/elililly.pdf)

### Novo Nordisk

**Wegovy pill reshaped Novo Nordisk’s media profile**

Novo Nordisk ranked 3rd of 10 by average monthly share of coverage (18.9%) in the Pharma in the UK benchmark for 2026 year to date, with 1,298 mentions and a net tone of +12.

Across January to October, Novo Nordisk recorded 1,298 mentions, representing 18.5% of tracked-company mentions on a pooled basis and 18.9% when monthly shares were weighted equally. It ranked fourth by pooled share but third by average monthly share, reflecting stronger visibility in some lower-volume months. January opened with second place and 22.4%, as reporting covered the US launch of oral Wegovy and UK approval of the 7.2mg dose. February’s fourth place and 20.0% coincided with the MHRA’s semaglutide vision-loss warning, the CagriSema trial shortfall and the European higher-dose approval. March and April returned Novo Nordisk to second place, with coverage spanning further sight-loss research, expanded NHS cardiovascular access and simplified Wegovy delivery requirements. Visibility fell to 18.5% and third place in May, when STEP UP and oral semaglutide trial analyses provided the principal product news. June produced the period’s highest share, 23.5%, alongside extensive reporting of the UK approval of oral Wegovy, although Novo Nordisk remained second. The pill’s private UK launch and European approval remained prominent in July, while August broadened the agenda through early uptake, financial performance, leadership strategy and the London drug-discovery partnership with AWS. Novo Nordisk stayed third in September as patient experience, prescribing safeguards, leadership appointments and licensing entered the mix, before falling to fourth and 12.7% in October. Taken together, the coverage established oral Wegovy as the central launch story while repeatedly returning to access, competitive pressure, patient safety and the prospects for Novo Nordisk’s wider pipeline.

Key messages:

- Novo Nordisk accounted for 18.5% of tracked-company mentions; its monthly rank ranged from second to fourth among ten companies.
- Coverage concentrated on Medicines Safety, Supply & Patient Use and Drug Approvals & Launches.
- Visibility peaked in June 2026 at 23.5%, compared with 12.7% in October 2026.
- January 2026: The Guardian reported Novo Nordisk’s US launch of the oral Wegovy pill and the resulting price competition.

Leading themes:

- Medicines Safety, Supply & Patient Use: 46.3% of Novo Nordisk's coverage (theme index 3.08, net tone −15)
- Drug Approvals & Launches: 19.2% of Novo Nordisk's coverage (theme index 4.01, net tone +47)
- NHS Access & Pricing: 10.6% of Novo Nordisk's coverage (theme index 1.12, net tone +32)

Notable positive coverage:

- 6 January 2026, dailymail.com: [Don't like fat jabs? Soon weight-loss drug Wegovy could be taken as a pill in UK after being launched in US](https://www.dailymail.com/news/article-15437117/fat-jabs-weight-loss-drug-Wegovy-pill-UK.html). Novo Nordisk launched an oral Wegovy treatment in the US and expects a UK MHRA decision on its application by the end of 2026. The article says Eli Lilly expects a comparable US regulatory decision in March.
- 12 January 2026, inews.co.uk: [What is 'natural Ozempic' - and how good is the science?](https://inews.co.uk/news/natural-ozempic-works-good-science-4156305). The article examines evidence behind a supplement marketed as "natural Ozempic" and contrasts it with GLP-1 medicines. It reports MHRA approval of Novo Nordisk's higher-dose Wegovy in the UK and discusses Mounjaro as a rival treatment.
- 12 January 2026, independent.co.uk: [Wegovy to launch stronger dose weight-loss jabs as UK usage set to soar](https://www.independent.co.uk/news/health/weight-loss-jab-wegovy-mounjaro-regulator-mhra-b2897695.html). The MHRA has approved Novo Nordisk's 7.2mg Wegovy dose for UK use, supported by trial results showing substantial weight loss. The article also reports evidence on GLP-1 medicine use, side effects and weight regain after treatment stops.

Notable negative coverage:

- 7 January 2026, irishnews.com: [People on fat loss jabs 'put weight back on faster than traditional dieters'](https://www.irishnews.com/news/uk/people-on-fat-loss-jabs-put-weight-back-on-faster-than-traditional-dieters-WKMTMQ2NENOUTE5MURKHSYNUK4/). Oxford researchers found rapid weight regain and loss of health benefits after stopping Wegovy or Mounjaro. The article discusses NHS treatment limits, private purchasing and potential nutritional risks.
- 6 February 2026, bmj.com: [GLP-1 drugs: New eyesight warning for Ozempic/Wegovy](https://www.bmj.com/content/392/bmj.s252). The BMJ reports an MHRA safety update warning that semaglutide may very rarely be associated with NAION. The article identifies Ozempic, Rybelsus and Wegovy as semaglutide brands.
- 1 July 2026, yahoo.com: [Sublingual semaglutide offered to UK practices despite Novo Nordisk concerns](https://www.yahoo.com/news/science/articles/sublingual-semaglutide-offered-uk-practices-115724571.html). An unlicensed sublingual semaglutide product is being marketed to UK private doctors despite not having MHRA approval. Novo Nordisk warned that mass compounding poses significant patient-safety risks.

- [Novo Nordisk deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd?entity=novonordisk&view=deep-dive)
- [Novo Nordisk PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd/reports/novonordisk.pdf)

### GSK

**Dealmaking and pipeline delivery reshaped GSK’s media profile**

GSK ranked 4th of 10 by average monthly share of coverage (18.8%) in the Pharma in the UK benchmark for 2026 year to date, with 1,319 mentions and a net tone of +49.

GSK recorded 1,319 mentions from January to October, representing 18.8% of tracked-company mentions and placing it fourth by average monthly share but third on the pooled measure. Its competitive position was volatile: monthly share ranged from 8.8% to 27.1%, while rank moved between first and fourth. Dealmaking supplied the clearest recurring thread, spanning the RAPT and 35Pharma acquisitions, the linerixibat licensing agreement and the announced $10.6bn Nuvalent deal. The Nuvalent transaction coincided with GSK’s move to first place in June, when its share rose by 9.5 percentage points to 27.1%. Pipeline evidence broadened the account beyond transactions, including bepirovirsen’s late-stage hepatitis B results, early Mo-Rez cancer data and the progression of an mRNA influenza vaccine into phase three. Corporate restructuring became more prominent in July, when GSK announced £1.9bn of annual savings, a £400m Cambridge research centre and the planned departure from Stevenage. July recorded 194 mentions and a 23.9% share, placing GSK second. Visibility then fell sharply in August before recovering in September alongside oncology licensing agreements with HUTCHMED and Chimagen. October extended the recovery to a period-high 218 mentions and a 23.3% share, but the news agenda combined encouraging osteosarcoma data with scrutiny of weaker vaccine sales, restructuring costs and planned Belgian job cuts.

Key messages:

- GSK accounted for 18.8% of tracked-company mentions; its monthly rank ranged from first to fourth among ten companies.
- Coverage concentrated on Financial Results & Pipeline and M&A & Licensing.
- Visibility peaked in June 2026 at 27.1%, compared with 8.8% in August 2026.
- January 2026: GSK agreed the $2.2bn acquisition of RAPT Therapeutics for food-allergy candidate ozureprubart, reported by The Guardian.

Leading themes:

- Financial Results & Pipeline: 27.9% of GSK's coverage (theme index 2.18, net tone +27)
- M&A & Licensing: 27.7% of GSK's coverage (theme index 2.14, net tone +73)
- Clinical Trials & Research: 12.3% of GSK's coverage (theme index 0.95, net tone +75)

Notable positive coverage:

- 11 January 2026, thetimes.com: [How likely is a GSK merger with AstraZeneca?](https://www.thetimes.com/business/companies-markets/article/how-likely-gsk-merger-with-astrazeneca-lq6rttfw3). Analyst speculation about a potential GSK-AstraZeneca merger was dismissed as unlikely by sources, with both companies focused on their existing strategies and pipelines. The article reviews their UK-listed corporate positions and leadership succession context.
- 20 January 2026, reuters.com: [GSK makes $2.2 billion swoop for RAPT Therapeutics' food allergy drug](https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-buy-rapt-therapeutics-22-billion-2026-01-20/). GSK agreed to acquire RAPT Therapeutics for $2.2 billion to gain rights to experimental food-allergy treatment ozureprubart. The transaction is the first major acquisition under CEO Luke Miels.
- 20 January 2026, thetimes.com: [GSK to buy US food allergy specialist for $2.2bn](https://www.thetimes.com/business/companies-markets/article/gsk-acquisition-buys-rapt-us-luke-miels-3jh3f0n0d). GSK is acquiring global rights to the food-allergy programme ozureprubart from RAPT and separately restructuring ViiV Healthcare's ownership. Pfizer will sell its 11.7% ViiV stake to Shionogi under the agreement.

Notable negative coverage:

- 17 July 2026, biopharmadive.com: [GSK shelves cough drug acquired in $2B deal](https://www.biopharmadive.com/news/gsk-camlipixant-cough-drug-shelved/825530/). GSK discontinued Phase 3 development of chronic-cough drug camlipixant after mixed results and failure to meet most trial goals. The setback removes a potential respiratory portfolio opportunity but analysts said it was not material to GSK's equity case.
- 29 October 2026, lse.co.uk: [London's FTSE 100 rises as Shell boosts energy stocks](https://www.lse.co.uk/news/londons-ftse-100-rises-as-shell-boosts-energy-stocks-tcgd3m4wgljchm1.html). GSK's disappointing results contributed to a further decline in London-listed pharmaceutical shares. Haleon's separate consumer-health forecast cut also weighed on the sector, though Haleon is not part of GSK.
- 30 April 2026, proactiveinvestors.co.uk: [JP Morgan retains 'underweight' on GSK with £17 price target as earnings upgrade potential seen as limited](https://www.proactiveinvestors.co.uk/companies/news/1091510/jp-morgan-retains-underweight-on-gsk-with-17-price-target-as-earnings-upgrade-potential-seen-as-limited-1091510.html). JP Morgan retained an underweight rating on GSK, citing limited near-term earnings upgrade potential. Its outlook depends on pipeline success and effective execution of new launches.

- [GSK deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd?entity=gsk&view=deep-dive)
- [GSK PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd/reports/gsk.pdf)

### Pfizer

**Pfizer’s profile shifted from access and deals towards research**

Pfizer ranked 5th of 10 by average monthly share of coverage (4.1%) in the Pharma in the UK benchmark for 2026 year to date, with 282 mentions and a net tone of 0.

Across January to October, Pfizer recorded 282 mentions and 4.0% of tracked-company mentions. It ranked fifth on both pooled share and its 4.1% average monthly share, placing it below the leading cohort but within the competitive middle tier. January delivered its highest share, at 6.1%, as reporting covered the ViiV Healthcare stake sale, NHS access for Talzenna and Scottish approval of Hympavzi. The profile narrowed in February and March, when Depo-Provera litigation and patient accounts became prominent, while the monthly rank moved from fifth to sixth despite March’s share rising to 4.6%. April’s 5.3% share coincided with wider eligibility for the Abrysvo RSV vaccine in England and evidence on maternal vaccination, alongside continuing Depo-Provera claims. Share then fell to 3.1% in May, although coverage included Pfizer’s 12-programme oncology collaboration with Innovent and a Full Fact check rejecting a false Covid-19 vaccine claim. June restored Pfizer to fifth place and 5.3%, with stories spanning the Innovent agreement, the Court of Appeal’s phenytoin pricing ruling, a regulatory complaint against Alnylam and a cancer frailty toolkit. Depo-Provera reporting remained prominent in July and August, while August also brought coverage of Pfizer’s 25-year green chemistry programme; share reached a period low of 1.6% and rank fell to seventh. September’s share recovered to 3.0%, with reporting on berobenatide, recruitment for a C. difficile vaccine trial and Pfizer’s US pricing agreement. October brought a further recovery to 4.0% and fifth place as research coverage expanded around the BEATRIX maternal vaccine study, forthcoming Lyme vaccine data and elranatamab’s potential NHS use.

Key messages:

- Pfizer accounted for 4% of tracked-company mentions; its monthly rank ranged from fifth to seventh among ten companies.
- Coverage concentrated on Medicines Safety, Supply & Patient Use and M&A & Licensing.
- Visibility peaked in January 2026 at 6.1%, compared with 1.6% in August 2026.
- January 2026: NICE reversed its provisional rejection and backed Talzenna with Xtandi for eligible NHS patients, reported by Pharmaceutical Technology.

Leading themes:

- Medicines Safety, Supply & Patient Use: 19.5% of Pfizer's coverage (theme index 0.93, net tone −84)
- M&A & Licensing: 18.4% of Pfizer's coverage (theme index 1.18, net tone +12)
- NHS Access & Pricing: 14.5% of Pfizer's coverage (theme index 1.54, net tone +2)

Notable positive coverage:

- 2 April 2026, bloomberg.com: [Pfizer's RSV Shot to Be Offered to 3 Million More in England](https://www.bloomberg.com/news/articles/2026-04-01/pfizer-s-rsv-shot-to-be-offered-to-3-million-more-in-england). England's NHS will expand eligibility for Pfizer's Abrysvo RSV vaccine to all adults aged 80 and over, covering about three million additional people. The expansion follows UKHSA evidence that vaccination substantially reduces hospitalisation risk.
- 9 October 2026, express.co.uk: [NHS major vaccine rollout for pensioners aged 65 to 74 continues in October](https://www.express.co.uk/news/uk/2255607/nhs-confirms-major-vaccine-rollout). NHS England and UKHSA are expanding RSV vaccination eligibility to clinically at-risk adults aged 65 to 74. The programme will continue to use Pfizer’s Abrysvo vaccine on a one-dose schedule.
- 1 July 2026, walesonline.co.uk: [NHS update as millions aged 65 to 74 can get jab from September 1](https://www.walesonline.co.uk/news/health/nhs-major-update-millions-aged-34219729). The NHS is expanding eligibility for Pfizer's Abrysvo RSV vaccine to certain at-risk adults aged 65 to 74 from 1 September. The MHRA-approved vaccine is also available to older adults, eligible pregnant women and care-home residents.

Notable negative coverage:

- 11 February 2026, theguardian.com: [UK law firms consider action on behalf of women who developed brain tumours after using contraceptive](https://www.theguardian.com/business/2026/feb/11/uk-law-firms-consider-action-on-behalf-of-women-who-developed-brain-tumours-after-using-contraceptive). UK law firms are considering claims against Pfizer on behalf of women who developed meningiomas after using Depo-Provera. Pfizer is contesting litigation and says it continuously monitors medicine safety with health authorities.
- 12 July 2026, independent.co.uk: ['I have an inoperable brain tumour after having the contraceptive jab'](https://www.independent.co.uk/news/health/brain-tumour-contraceptive-injection-depo-provera-b3011322.html). UK women taking legal action against Pfizer allege a link between long-term Depo-Provera use and meningioma brain tumours. Pfizer says the contraceptive has an established efficacy and safety profile, while the MHRA says safety is continually reviewed.
- 2 July 2026, mirror.co.uk: [Nurse took contraceptive jab for years - now she has 'devastating' brain tumours](https://www.mirror.co.uk/news/uk-news/brain-tumour-contraceptive-injection-symptom-37378744). Women in Scotland are pursuing potential legal claims alleging that long-term use of Pfizer-manufactured Depo-Provera caused brain tumours. Pfizer and the MHRA say the medicine's safety is continually monitored.

- [Pfizer deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd?entity=pfizer&view=deep-dive)
- [Pfizer PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd/reports/pfizer.pdf)

### MSD

**MSD coverage spans NHS access, cancer research and patent disputes**

MSD ranked 6th of 10 by average monthly share of coverage (3.3%) in the Pharma in the UK benchmark for 2026 year to date, with 218 mentions and a net tone of +21.

MSD recorded 218 mentions from January to October, ranking sixth by both its 3.3% average monthly share and 3.1% pooled share of tracked-company mentions. Its monthly position ranged from ninth in January and March to fifth in May and August, with the strongest share appearing in May at 7.2%. Early coverage included the Guardant Health oncology collaboration and planned $9.2bn Cidara acquisition, followed by favourable UK developments in the Keytruda SC patent dispute in February. March combined a lower 2.3% share with NICE's recommendation of Keytruda for perioperative treatment of locally advanced head and neck cancer. April broadened the agenda through Enflonsia's UK authorisation, reporting on MSD's withdrawal from Belgrove House and investigations into Keytruda pricing and patent strategy. MSD's share then rose to 7.2% in May, when reporting centred on the rapid injectable Keytruda rollout and NICE's recommendation of Winrevair for pulmonary arterial hypertension. June and July brought further NHS access for Keytruda in locally advanced cervical cancer and a Dutch court decision dismissing Halozyme's preliminary-injunction bid. Clinical research became more prominent in August, while the only September article centred specifically on MSD compared its oncology portfolio and growth strategy with AstraZeneca's. October's 3.4% share and sixth place coincided with extensive reporting on phase-three melanoma vaccine results and a Dutch ruling restricting Keytruda SC in eight European countries. Across the period, MSD's profile moved between access gains, oncology research and legal scrutiny, while contextual mentions frequently placed its medicines and UK investment stance within broader competitive and policy debates.

Key messages:

- MSD accounted for 3.1% of tracked-company mentions; its monthly rank ranged from fifth to ninth among ten companies.
- Coverage concentrated on Clinical Trials & Research and NHS Access & Pricing.
- Visibility peaked in May 2026 at 7.2%, compared with 2.3% in March 2026.
- January 2026: Merck and Guardant Health entered a multiyear oncology diagnostics collaboration, reported by Fierce Biotech.

Leading themes:

- Clinical Trials & Research: 28.0% of MSD's coverage (theme index 2.28, net tone +56)
- NHS Access & Pricing: 22.0% of MSD's coverage (theme index 2.39, net tone +17)
- M&A & Licensing: 15.1% of MSD's coverage (theme index 0.96, net tone +21)

Notable positive coverage:

- 23 October 2026, aol.co.uk: [First personalised cancer vaccine cuts risk of disease returning in major trial](https://www.aol.co.uk/articles/world-first-personalised-cancer-vaccine-074907000.html). A UK-involving phase-three melanoma trial found that MSD’s Keytruda combined with Moderna’s personalised mRNA cancer vaccine Intismeran reduced the risk of recurrence, death or disease spread versus immunotherapy alone. The companies are testing the approach in other cancers and may seek regulatory approval next year, although experts said longer follow-up is needed.
- 23 October 2026, bbc.co.uk: [First personalised cancer vaccine stops disease returning in major trial](https://www.bbc.co.uk/news/articles/cq0ld9g9e913o). A major melanoma trial involving UK patients found that MSD’s Keytruda combined with Moderna’s personalised mRNA vaccine Intismeran reduced the risk of recurrence or death by 42%. The companies are engaging regulators ahead of potential filings, while experts say longer follow-up is needed and future NHS use will depend on cost.
- 24 October 2026, newswire.lk: [A major step forward in cancer treatment? New vaccine delivers promising results](https://www.newswire.lk/2026/10/24/a-major-step-forward-in-cancer-treatment/). A personalised mRNA cancer-vaccine trial at Addenbrooke’s Hospital, used alongside MSD’s Keytruda, reported reduced risks of melanoma recurrence, death and spread versus Keytruda alone. The phase-three findings are not yet peer-reviewed and would require regulatory approval before potential NHS availability.

Notable negative coverage:

- 13 April 2026, thebureauinvestigates.com: [Keytruda: what’s the true cost of the world’s bestselling cancer drug?](https://www.thebureauinvestigates.com/stories/2026-04-13/keytruda-whats-the-true-cost-of-the-worlds-bestselling-cancer-drug). An investigation examines the NHS cost of MSD's Keytruda, arguing that confidential pricing and dosing practices may lead to substantial overspending. It also reports on the drug's patent strategy and MSD's cancelled London R&D investment.
- 8 October 2026, biz.chosun.com: [Halozyme court win halts Keytruda SC in Europe, puts Alteogen royalties at risk - CHOSUNBIZ](https://biz.chosun.com/en/en-science/2026/10/08/ZUKZCXYYSNATBL37BL7SQWF22Y/?outputType=amp). A Dutch court barred MSD's Keytruda SC in eight European countries after finding infringement of Halozyme's drug-delivery patent. The report notes that the relevant UK patent was revoked and that MSD previously received a favourable UK outcome.
- 27 April 2026, building.co.uk: [Developer behind Mace’s King’s Cross life sciences building working with agents to find new occupiers after end-user pulled out last year](https://www.building.co.uk/news/developer-behind-maces-kings-cross-life-sciences-building-working-with-agents-to-find-new-occupiers-after-end-user-pulled-out-last-year/5141948.article). MSD withdrew from plans to occupy Belgrove House in King's Cross, citing UK competitiveness and medicines pricing. The developer is now seeking replacement occupiers for the London life-sciences building.

- [MSD deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd?entity=msd&view=deep-dive)
- [MSD PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd/reports/msd.pdf)

### Novartis

**Myricx acquisition was Novartis’s most extensively covered development**

Novartis ranked 7th of 10 by average monthly share of coverage (2.9%) in the Pharma in the UK benchmark for 2026 year to date, with 206 mentions and a net tone of +32.

Across January to October, Novartis recorded 206 mentions and ranked joint seventh with Roche by both pooled and average monthly share, each at 2.9% of tracked-company mentions. Its position varied from fifth in July to tenth in April and June, with the strongest visibility concentrated in the second half of the window. Early coverage offered limited evidence of activity at Novartis: January included its sponsored advanced breast cancer awareness campaign, while many February and March articles referred to the company only contextually within broader sector reporting. April brought reporting on the withdrawal of the EU Pluvicto label-expansion filing and the chief executive’s call for a rethink of European drug pricing. May broadened the profile through NHS collaboration, including cancer-patient information videos supported with NHS Greater Glasgow and Clyde, alongside sponsored commentary on partnerships with Gateshead Health and The Royal Marsden. In July, Novartis reached its strongest monthly position at 5.2% and fifth place, while extensive reporting covered the agreed acquisition of Myricx Bio and a separate NHS decision expanding routine access to Tafinlar. August shifted towards the successful defence of Entresto’s UK patent, the MHRA authorisation of Rhapsido and the Check Her Out breast-cancer campaign. September combined continued reporting on the Entresto decision and an MS advocacy partnership with coverage of the pause in autoimmune CAR-T trials after three patient deaths. October added the Abogen mRNA licensing agreement, a regional NHS innovation partnership and reporting that Novartis had raised full-year guidance despite trial setbacks and declining Entresto sales. Overall, the profile developed from sparse and often contextual visibility into a more varied mix of transactions, access, intellectual property, patient initiatives and pipeline scrutiny.

Key messages:

- Novartis accounted for 2.9% of tracked-company mentions; its monthly rank ranged from fifth to tenth among ten companies.
- Coverage concentrated on M&A & Licensing and Financial Results & Pipeline.
- Visibility peaked in July 2026 at 5.2%, compared with 1.3% in February 2026.
- January 2026: Novartis UK funded an advanced breast-cancer awareness campaign focused on patient experiences and gaps in specialist support, published as sponsored content by Metro.

Leading themes:

- M&A & Licensing: 33.5% of Novartis's coverage (theme index 2.2, net tone +46)
- Financial Results & Pipeline: 10.7% of Novartis's coverage (theme index 0.68, net tone 0)
- NHS Access & Pricing: 10.2% of Novartis's coverage (theme index 1.06, net tone +14)

Notable positive coverage:

- 6 July 2026, finance.yahoo.com: [Novartis to acquire UK-based Myricx Bio for up to $1.5 billion](https://finance.yahoo.com/healthcare/articles/novartis-acquire-uk-based-myricx-052604806.html). Novartis has agreed to acquire London-based Myricx Bio for up to $1.5 billion. Myricx develops antibody-drug conjugates for cancer treatment.
- 6 July 2026, manilatimes.net: [Brandon Capital Announces Agreement for Novartis to Acquire Portfolio Company Myricx Bio to Advance New Class of Cancer Therapeutics](https://www.manilatimes.net/2026/07/06/tmt-newswire/globenewswire/brandon-capital-announces-agreement-for-novartis-to-acquire-portfolio-company-myricx-bio-to-advance-new-class-of-cancer-therapeutics/2378736). Novartis agreed to acquire UK-based Myricx Bio for up to $1.5bn, including milestone payments. The acquisition brings Myricx's pre-clinical oncology ADC platform into Novartis's oncology business.
- 6 July 2026, pharmaceutical-technology.com: [Novartis to buy Myricx Bio in up to $1.5bn deal](https://www.pharmaceutical-technology.com/news/novartis-to-acquire-myricx-bio/). Novartis agreed to acquire UK-based cancer biotech Myricx Bio for up to $1.5bn. The deal adds Myricx's preclinical NMTi antibody-drug-conjugate payload platform to Novartis's oncology pipeline.

Notable negative coverage:

- 14 February 2026, thetimes.com: [NHS drug rules 'killing' UK life sciences, says pharma boss](https://www.thetimes.com/business/companies-markets/article/nhs-drug-rules-killing-uk-life-sciences-says-pharma-boss-hgkqssjkz). Novartis criticises NICE cost-effectiveness rules and says restricted NHS access has contributed to reduced UK investment and employment. The article covers the planned increase in NICE thresholds and broader concerns about UK life-sciences competitiveness.
- 16 June 2026, mlex.com: [Accord challenges Novartis blood pressure medicine patent in UK court](https://www.mlex.com/mlex/articles/2490151/accord-challenges-novartis-blood-pressure-medicine-patent-in-uk-court). Accord Healthcare is challenging Novartis' English patent for heart-failure medicine Entresto ahead of a proposed generic launch. The case concerns the validity of the patent.
- 9 September 2026, tikr.com: [Amgen Stock Sank 9.6% After Novartis’s Trial Failure and a Tavneos Suspension](https://www.tikr.com/blog/amgen-stock-sank-9-6-after-novartiss-trial-failure-and-a-tavneos-suspension). The article reports the MHRA’s suspension of new-patient use of Amgen’s Tavneos and planned withdrawal of its UK marketing authorisation. It also discusses Novartis’s late-stage cardiovascular trial failure and positive Phase 3 Tezspire results from Amgen and AstraZeneca.

- [Novartis deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd?entity=novartis&view=deep-dive)
- [Novartis PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd/reports/novartis.pdf)

### Roche

**Roche visibility centred on diagnostics, Alzheimer’s research and dealmaking**

Roche ranked 7th of 10 by average monthly share of coverage (2.9%) in the Pharma in the UK benchmark for 2026 year to date, with 200 mentions and a net tone of +27.

Roche recorded 200 mentions from January to October, representing 2.9% of tracked-company mentions and joint seventh place with Novartis by both pooled and average monthly share. Its competitive position was volatile: monthly share ranged from 0.3% and tenth place in February to 5.2% and fifth place in March. The available February articles referred to Roche only in wider sector coverage, whereas January included NICE’s support for Gazyvaro in lupus nephritis, positive CT-388 weight-loss data and Roche Diagnostics’ backing for an NHS cervical-screening campaign. March’s rebound coincided with Roche’s sustainable-healthcare scholarship and its successful complaint over Bayer’s pre-authorisation promotion, although much of the clinical-research total came from contextual comparisons with AstraZeneca’s COPD results. April broadened the profile through the UK introduction of Accu-Chek SmartGuide and the Roche chief executive’s warning about European pricing and regulation. Subsequent developments included the CE Mark for the Elecsys Alzheimer’s blood test, advanced multiple-sclerosis results for ocrelizumab and the launch of the Axelios gene-sequencing platform. July added the Genentech-Astex breast-cancer alliance, a Scottish study of Roche Alzheimer’s blood tests and Scottish access for the Columvi combination. After Roche fell to tenth place in August, when coverage included the zilebesiran hypertension trial and its UKHSA partnership, September returned it to fifth as the PrevenTRON trontinemab trial opened in Europe and Gazyvaro gained MHRA authorisation. October closed with Roche seventh on 3.3%, alongside its Hansoh development deal, a prospective lung-cancer treatment, the Itovebi rejection by NICE and settlement of the Perjeta biosimilar dispute. Across the period, Roche’s profile moved between access, diagnostics and research, with licensing, oncology and intellectual-property matters becoming more prominent later in the window.

Key messages:

- Roche accounted for 2.9% of tracked-company mentions; its monthly rank ranged from fifth to tenth among the ten companies.
- Coverage concentrated on Clinical Trials & Research and M&A & Licensing.
- Visibility peaked in March 2026 at 5.2%, compared with 0.3% in February 2026.
- January 2026: NICE backed Roche’s Gazyvaro for lupus nephritis, reported by pharmaphorum.

Leading themes:

- Clinical Trials & Research: 27.0% of Roche's coverage (theme index 2.19, net tone +11)
- M&A & Licensing: 20.5% of Roche's coverage (theme index 1.31, net tone +24)
- NHS Access & Pricing: 13.0% of Roche's coverage (theme index 1.36, net tone +15)

Notable positive coverage:

- 7 September 2026, pharmaphorum.com: [Major trial of Roche Alzheimer's drug kicks off in Europe](https://pharmaphorum.com/news/major-trial-roche-alzheimers-drug-kicks-europe). A UK NHS trust is the first European site to enrol patients in Roche's phase 3 PrevenTRON trial of trontinemab for preventing or delaying Alzheimer's disease. The global study will recruit around 1,600 cognitively healthy people at high risk of the disease.
- 30 September 2026, thesun.co.uk: [New weight jab 'burns fat with half the side effects' of Mounjaro and Wegovy](https://www.thesun.co.uk/health/40537552/weight-loss-injection-petrelintide-fewer-side-effects/). Trial data suggest Roche and Zealand Pharma's experimental obesity injection petrelintide produced around 10% average weight loss over 42 weeks, with fewer reported gastrointestinal side effects than existing injections. The article notes that petrelintide has not been directly compared with Wegovy or Mounjaro and remains in trials.
- 5 September 2026, mirror.co.uk: [Alzheimer's drug to be offered to people without symptoms to stop it developing](https://www.mirror.co.uk/news/health/alzheimers-drug-cure-symptoms-dementia-37631556). Roche is globally sponsoring the Phase III PrevenTRON trial, which will give trontinemab to healthy UK participants at risk of Alzheimer's disease. Surrey and Borders Partnership NHS Foundation Trust is the first European site to open the study.

Notable negative coverage:

- 15 October 2026, pharmaphorum.com: [Roche breast cancer drug Itovebi turned down by NICE](https://pharmaphorum.com/news/roche-breast-cancer-drug-itovebi-turned-down-nice). NICE has declined to recommend routine NHS use of Roche's Itovebi combination for a form of advanced breast cancer, citing cost-effectiveness and evidence uncertainties. Roche described the outcome as devastating for patients and called for reform of the UK medicines-value assessment system.
- 16 October 2026, genomeweb.com: [NICE Does Not Recommend Itovebi Regimen in Advanced Breast Cancer](https://www.genomeweb.com/business-news/reimbursement/gnw-itovebi-nice-nhs-uk-rejects-coverage-20261015/). NICE's final draft guidance does not recommend Roche's Itovebi-based breast-cancer regimen after Roche and NHS England failed to agree a cost-effective price. Roche called the decision devastating for eligible patients and criticised the UK's approach to valuing innovative combination medicines.

- [Roche deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd?entity=roche&view=deep-dive)
- [Roche PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd/reports/roche.pdf)

### Sanofi

**NHS access anchored Sanofi amid a volatile competitive year**

Sanofi ranked 9th of 10 by average monthly share of coverage (2.5%) in the Pharma in the UK benchmark for 2026 year to date, with 174 mentions and a net tone of +1.

Sanofi recorded 174 mentions from January to October, representing 2.5% of tracked-company mentions and placing ninth by both pooled and average monthly share. Its position varied considerably: it ranked seventh in January, February and March, rose to sixth in June, but ranked tenth in May, July and October. January combined Dupixent’s NICE recommendation for uncontrolled COPD with Ahmed Moussa’s appointment as UK and Ireland country lead, while analysts separately questioned the strength of Sanofi’s pipeline. February’s agenda shifted towards the PMCPA findings over Beyfortus claims and Sanofi’s participation in Altesa BioSciences’ $75 million financing for a rhinovirus programme. Sanofi’s share rose to 4.0% in March, when its agreement to supply Nuvaxovid JN.1 for the UK spring vaccination programme appeared alongside numerous contextual comparisons between its earlier COPD research and AstraZeneca’s successful tozorakimab trials. The available April and May articles largely mentioned Sanofi in wider reporting on medicine pricing, investment, vaccine supply and competing COPD treatments rather than reporting developments at the company. June brought Sanofi’s strongest competitive position, alongside NICE’s recommendation of Tzield for early-stage type 1 diabetes and the UK authorisation of subcutaneous Sarclisa. Its share then fell to 1.4% in July and remained at that level in August, as reporting covered Sanofi’s stated aim to rebuild and potentially expand its partnership with Regeneron, further scrutiny of Beyfortus promotion and disruption to UK flu-vaccine supplies. September and October broadened the agenda through continued examination of teplizumab access, a mature-medicines partnership with Cheplapharm, the ScionxBio mRNA collaboration, an NHS severe-asthma project and the Tackle Diabetes campaign. Across the window, Sanofi’s media profile moved from concentrated access and regulatory stories towards a more varied combination of partnerships, delivery innovation, public education and pipeline development, although its final monthly rank remained tenth.

Key messages:

- Sanofi accounted for 2.5% of tracked-company mentions; its monthly rank ranged from sixth to tenth among ten companies.
- Coverage concentrated on NHS Access & Pricing and Clinical Trials & Research.
- Visibility peaked in March 2026 at 4%, compared with 1.4% in July 2026.
- January 2026: PMLiVE reported NICE’s positive final draft guidance for Sanofi and Regeneron’s Dupixent in uncontrolled COPD.

Leading themes:

- NHS Access & Pricing: 20.7% of Sanofi's coverage (theme index 2.21, net tone +53)
- Clinical Trials & Research: 20.1% of Sanofi's coverage (theme index 1.6, net tone −26)
- Financial Results & Pipeline: 12.6% of Sanofi's coverage (theme index 0.8, net tone −5)

Notable positive coverage:

- 27 January 2026, pmlive.com: [Sanofi and Regeneron's Dupixent receives positive NICE final draft guidance for COPD](https://pmlive.com/pharma_news/sanofi-and-regenerons-dupixent-receives-positive-nice-final-draft-guidance-for-copd/). NICE issued positive final draft guidance recommending Sanofi and Regeneron's Dupixent for NHS reimbursement for eligible adults with uncontrolled COPD. Sanofi UK said it would work to support implementation if final guidance is issued.
- 23 June 2026, pharmaphorum.com: [Sanofi's type 1 diabetes-delaying drug cleared for NHS use](https://pharmaphorum.com/news/sanofis-type-1-diabetes-delaying-drug-cleared-nhs-use). NICE final draft guidance recommends Sanofi's Tzield for eligible early-stage type 1 diabetes patients in England and Wales. The medicine will be supplied to the NHS at a confidential discount.
- 23 June 2026, diabetestimes.co.uk: [Sanofi’s teplizumab becomes first licensed disease-modifying treatment in the UK to delay the onset of symptomatic type 1 diabetes](https://diabetestimes.co.uk/sanofis-teplizumab-becomes-first-licensed-disease-modifying-treatment-in-the-uk-to-delay-the-onset-of-symptomatic-type-1-diabetes/). NICE final draft guidance recommends Sanofi’s teplizumab for NHS reimbursement for eligible people with stage 2 type 1 diabetes. The article describes the treatment as the first UK licensed disease-modifying option to delay symptomatic disease.

Notable negative coverage:

- 2 February 2026, bloomberg.com: [Sanofi Rebuked in UK Over RSV Claims Targeting Rival Pfizer Shot](https://www.bloomberg.com/news/articles/2026-02-02/sanofi-rebuked-in-uk-over-rsv-claims-targeting-rival-pfizer-shot). UK self-regulatory body PMCPA found Sanofi made misleading claims about Beyfortus and disparaged Pfizer's RSV vaccine. Sanofi accepted the findings and said it had strengthened internal compliance processes.
- 2 February 2026, reuters.com: [UK industry body says Sanofi in breach over RSV therapy claims against Pfizer](https://www.reuters.com/business/healthcare-pharmaceuticals/uk-industry-body-says-sanofi-breach-over-rsv-therapy-claims-against-pfizer-2026-02-02/). The UK PMCPA found Sanofi breached the pharmaceutical code over unsubstantiated public claims that Beyfortus was more effective than Pfizer's RSV vaccine. Sanofi accepted the findings following Pfizer's complaint.
- 25 August 2026, chemistanddruggist.co.uk: [CSL Seqirus providing additional flu vaccines following stock disruption](https://www.chemistanddruggist.co.uk/news/business/csl-seqirus-providing-additional-flu-vaccines-following-stock-disruption-JNOGL442QJET3CVYBI4LOICF5I/). NHS England said a supply issue affected Sanofi's Supemtek TIVr influenza vaccine, although sufficient stock remains available for the 2026-27 flu programme. CSL Seqirus is providing alternative vaccine supplies to help address the disruption.

- [Sanofi deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd?entity=sanofi&view=deep-dive)
- [Sanofi PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd/reports/sanofi.pdf)

### Moderna

**UK partnerships and cancer vaccines broaden Moderna’s media profile**

Moderna ranked 10th of 10 by average monthly share of coverage (2.4%) in the Pharma in the UK benchmark for 2026 year to date, with 170 mentions and a net tone of +59.

Moderna recorded 170 mentions from January to October, representing 2.4% of tracked-company mentions and placing it tenth by both pooled and average monthly share. Its position varied materially within that result, from tenth place and 0.4% in March to sixth place in April and August and joint sixth in May. Early coverage combined improved revenue guidance and cost control with durable melanoma-immunotherapy findings and the UK government partnership. February’s rise to eighth coincided with regulatory approval for UK-manufactured Spikevax, alongside scrutiny of the FDA’s refusal to review Moderna’s flu-vaccine filing and its reorganisation of research spending. After limited contextual visibility in March, April’s advance to 4.3% coincided with extensive reporting on the UK-US Phase 3 trial of Moderna’s H5 bird-flu vaccine. First-quarter results then put international COVID-19 vaccine sales and the first UK government shipment at the centre of May’s financial coverage. The emphasis returned to research in June as Moderna and Oxford prepared a UK trial of an mRNA vaccine intended to prevent cancers associated with Lynch syndrome. July coverage paired stronger-than-expected second-quarter revenue and a narrower loss with the norovirus vaccine’s failure to meet interim statistical criteria. August restored Moderna to sixth place as Phase 3 melanoma results and the first participant dosed in the Lynch syndrome study extended the company’s profile beyond respiratory vaccines. By September and October, the agenda combined an MHRA-authorised updated Spikevax vaccine, the loss of a key European mRNA patent, manufacturing strategy and fuller reporting on the personalised melanoma vaccine’s Phase 3 findings.

Key messages:

- Moderna accounted for 2.4% of tracked-company mentions; its monthly rank ranged from sixth to tenth among ten companies.
- Coverage concentrated on Clinical Trials & Research and Vaccines & Public Health.
- Visibility peaked in April 2026 at 4.3%, compared with 0.4% in March 2026.
- February 2026: MHRA approval of UK-manufactured Spikevax for NHS use — The Independent.

Leading themes:

- Clinical Trials & Research: 52.9% of Moderna's coverage (theme index 4.5, net tone +76)
- Vaccines & Public Health: 18.2% of Moderna's coverage (theme index 6.49, net tone +55)
- Financial Results & Pipeline: 14.1% of Moderna's coverage (theme index 0.9, net tone +17)

Notable positive coverage:

- 21 April 2026, reuters.com: [Moderna starts late-stage trial of bird flu vaccine in US, UK](https://www.reuters.com/legal/litigation/moderna-starts-late-stage-trial-bird-flu-vaccine-us-uk-2026-04-21/). Moderna has started a late-stage trial of its experimental mRNA bird-flu vaccine in the US and UK, involving around 4,000 healthy adults.
- 22 April 2026, pharmaphorum.com: [Pivotal trial of Moderna's H5N1 bird flu jab gets underway](https://pharmaphorum.com/news/pivotal-trial-modernas-h5n1-bird-flu-jab-gets-underway). Moderna has begun a pivotal UK-US trial of its mRNA-1018 H5N1 bird flu vaccine, with around three-quarters of participants recruited in the UK. The article links the UK trial footprint to Moderna's UK vaccine facility and relationship with the country.
- 9 June 2026, independent.co.uk: [Oxford University and Moderna to trial pioneering cancer vaccine](https://www.independent.co.uk/bulletin/news/cancer-vaccine-uk-moderna-oxford-university-b2992196.html). Moderna and Oxford University are preparing a UK trial of a cancer-prevention vaccine for patients with Lynch syndrome. The study will evaluate whether the mRNA vaccine can eliminate pre-cancerous cells.

Notable negative coverage:

- 18 September 2026, juve-patent.com: [EPO revokes key Moderna patent for mRNA vaccines](https://www.juve-patent.com/people-and-business/epo-revokes-key-moderna-patent-for-mrna-vaccines/). The European Patent Office has revoked a key Moderna mRNA-vaccine patent following opposition involving Pfizer and BioNTech. The ruling reverses a patent position that had supported Moderna's earlier litigation successes, including in London.
- 14 February 2026, endpoints.news: [Moderna vs FDA; Paul Hudson out at Sanofi; Why clinical trials are so costly; and more](https://endpoints.news/moderna-vs-fda-paul-hudson-out-at-sanofi-why-clinical-trials-are-so-costly-and-more/). A biopharma weekly roundup reports an FDA refusal-to-file for Moderna’s flu vaccine, Sanofi’s CEO change and pipeline setbacks, and AstraZeneca’s positive Phase 2 obesity-pill results. AstraZeneca plans to begin Phase 3 trials of elecoglipron this year.
- 16 October 2026, aol.co.uk: [Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady](https://www.aol.co.uk/articles/novavax-plunges-12-selloff-hits-164410000.html). Novavax shares fell sharply alongside Moderna as vaccine stocks sold off, while Pfizer was broadly flat. Sanofi, Novavax's licensing partner, is rolling out the Nuvaxovid Covid-19 vaccine in the UK, Germany and Canada, with Novavax's royalty prospects dependent on that commercialisation.

- [Moderna deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd?entity=moderna&view=deep-dive)
- [Moderna PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd/reports/moderna.pdf)

## Methodology

- **Share of coverage**: an organisation's mentions divided by all mentions of the organisations tracked in the same sector that month, in UK earned media. It is the central measure of media visibility in Omniscan benchmarks. "Average monthly share" is the mean of the monthly shares across the reporting period.
- **Mention**: one article that covers an organisation, classified as positive, neutral or negative in tone. Articles are deduplicated, and an organisation's own websites and passing sponsorship name-checks are excluded, so only earned media counts.
- **Net tone**: positive mentions minus negative mentions, as a percentage of all mentions (range −100 to +100).
- **Themes**: every article is assigned to one of the sector's editorial themes. A theme index above 1 means the organisation is covered on that theme more than its peers are; below 1 means less.
- **Calculation**: every figure is computed directly from the classified articles; narrative summaries are checked against those figures.
- **Sources**: UK national and international, trade and specialist, regional and local, and aggregator and syndication media coverage, including sponsored and contributed material.

## Other Pharma in the UK editions

- [UK pharma media reputation tracker – H1 2026](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1.md)
- [UK pharma media reputation tracker – July 2026](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07.md)
- [UK pharma media reputation tracker – August 2026](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08.md)
- [UK pharma media reputation tracker – September 2026](https://www.omniscan.ai/benchmarks/uk-pharma-2026-09.md)
- [UK pharma media reputation tracker – October 2026](https://www.omniscan.ai/benchmarks/uk-pharma-2026-10.md)
- [All Omniscan media benchmarks](https://www.omniscan.ai/benchmarks.md)

## How to cite

Omniscan, "UK pharma media reputation tracker", 2026 year to date (1 January 2026–31 October 2026), published 3 November 2026. https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd
